1 141

Cited 21 times in

Quality of Life in the Trastuzumab for Gastric Cancer Trial

 Taroh Satoha  ;  Yung-Jue Bangb  ;  Evgeny A. Gotovkinc  ;  Yasuo Hamamotod  ;  Yoon-Koo Kange  ;  Vladimir M. Moiseyenkof  ;  Atsushi Ohtsug  ;  Eric Van Cutsemh  ;  Nedal Al-Sakaffi  ;  Alexa Urspruchi  ;  Julie Hillj  ;  Harald A. Weberi  ;  Hyun-Cheol Chung 
 ONCOLOGIST, Vol.19(7) : 712-719, 2014 
Journal Title
Issue Date
Antibodies, Monoclonal, Humanized/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Capecitabine ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Fluorouracil/analogs & derivatives ; Humans ; Quality of Life ; Receptor, ErbB-2/metabolism ; Stomach Neoplasms/drug therapy* ; Stomach Neoplasms/enzymology ; Surveys and Questionnaires ; Trastuzumab
Chemotherapy ; Gastric cancer ; HER2 ; Quality of life ; Trastuzumab
BACKGROUND: The Trastuzumab for Gastric Cancer phase III trial demonstrated that combining trastuzumab with chemotherapy significantly improved overall survival compared with chemotherapy alone in HER2-positive advanced gastric or gastroesophageal junction cancer. We report health-related quality of life (HRQoL) and quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) results from this trial. PATIENTS AND METHODS: Patients were randomized to receive six cycles of chemotherapy given every 3 weeks (capecitabine or fluorouracil, plus cisplatin) either alone or combined with administration of trastuzumab every 3 weeks until disease progression. At each clinical visit, HRQoL was assessed using two European Organization for Research and Treatment of Cancer quality of life questionnaires, QLQ-C30 and QLQ-STO22. Q-TWiST methodology was applied retrospectively using the clinical data and utility coefficients. RESULTS: Trastuzumab plus chemotherapy prolonged time to 10% definitive deterioration in all QLQ-C30 and QLQ-STO22 scores, including QLQ-C30 global health status versus chemotherapy alone, from 6.4 months to 10.2 months. In addition, trastuzumab plus chemotherapy extended Q-TWiST by 2.42 months compared with chemotherapy alone. CONCLUSION: Compared with chemotherapy alone, trastuzumab plus chemotherapy prolongs time to deterioration of HRQoL and increases quality-adjusted survival in patients with HER2-positive gastric or gastroesophageal junction cancer.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.